Novo Nordisk Hands Parkinson’s Therapy to AI Startup, Taking Stake in Boston-Based Cellular Intelligence
Updated
Updated · Bloomberg · May 11
Novo Nordisk Hands Parkinson’s Therapy to AI Startup, Taking Stake in Boston-Based Cellular Intelligence
13 articles · Updated · Bloomberg · May 11
Cellular Intelligence will take over Novo Nordisk’s experimental Parkinson’s therapy and lead the early-stage program through clinical trials under a deal announced Monday.
Novo said the handoff is meant to speed development of the treatment, shifting execution to the Mark Zuckerberg-backed startup as the program advances.
Novo could receive milestone payments and royalties if the therapy succeeds, while also buying an equity stake in the Boston-based company.
No financial terms were disclosed, leaving the value of the Parkinson’s partnership unclear as Novo broadens ties beyond its Wegovy-led core business.
Can an AI startup truly outpace biology's limits to fast-track a Parkinson's drug for a pharma giant?
When an AI designs a drug trial, who is liable if its 'black box' predictions cause patient harm?
Novo Nordisk Hands Off Parkinson’s Cell Therapy to AI Startup Cellular Intelligence in $62M-Backed Deal, Marking Major Strategic Shift
Overview
Novo Nordisk has formed a strategic partnership with Cellular Intelligence to accelerate the development of an experimental Parkinson’s disease therapy. By transferring the rights to its early-stage treatment, Novo Nordisk allows Cellular Intelligence to take the lead in guiding the therapy through clinical trials. This collaboration leverages Cellular Intelligence’s advanced AI capabilities to speed up the process, while Novo Nordisk stands to receive milestone payments and royalties if the program succeeds. The partnership reflects Novo Nordisk’s shift in focus and highlights how AI-driven biotech startups can play a key role in advancing complex therapies more efficiently.